Browse the evidence

Ingestion of short-chain fatty acids (SCFAs), specifically propionate and butyrate, stimulates PYY gene expression and secretion in human enteroendocrine cells via histone deacetylase (HDAC) inhibition, thereby increasing plasma PYY levels.

To maximize your natural PYY production (a hormone that helps you feel full), focus on consuming high-fiber foods that your gut bacteria can ferment into short-chain fatty acids like butyrate and propionate. This process naturally stimulates your gut hormones to regulate appetite, a mechanism that works specifically in humans.

Evening exposure to blue-enriched light (peak sensitivity ~460-477 nm) suppresses melatonin secretion and shifts circadian phase, with effects occurring rapidly and recovering quickly upon cessation.

If you are sensitive to sleep disruption, minimize exposure to bright, blue-rich light (LEDs, screens) in the 2 hours before bed. Even low levels (5-10 lux) can trigger circadian responses. If you must use light, choose warmer colors (longer wavelengths >600nm) and keep intensity low. Note that effects reverse quickly once the light is off.

SGLT2 inhibitors reduce major adverse cardiovascular events (MACE) by 11% and heart failure hospitalization by 23% in patients with type 2 diabetes and established cardiovascular disease.

If you have Type 2 Diabetes and heart disease or heart failure, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs not only help control blood sugar but have been proven to significantly reduce the risk of heart attacks, strokes, and hospitalizations for heart failure, regardless of your current blood sugar levels.

High-fat diet consumption triggers rapid hypothalamic inflammation (via TLR4/JNK/NF-κB pathways) that causes central insulin and leptin resistance, uncoupling energy balance and driving obesity.

Focus on reducing saturated fats (like palmitic acid) in your diet, as they directly trigger brain inflammation that blocks satiety hormones. This isn't just about calories; it's about protecting your brain's ability to regulate hunger and metabolism.

Saturated fatty acids (SFAs) like palmitate cross the blood-brain barrier and accumulate in the hypothalamus, directly causing insulin and leptin resistance via TLR4 and JNK activation.

Limit intake of saturated fats (found in fatty meats, butter, cheese) to prevent them from entering the brain and blocking weight-regulating hormones.

Hypothalamic inflammation disrupts the blood-brain barrier (BBB), allowing peripheral inflammatory signals and immune cells to enter the brain, further exacerbating metabolic deregulation.

Long-term high-fat diets damage the brain's protective barrier, letting inflammation in. Reducing saturated fats may help maintain this barrier.

Physical activity and sleep duration are highly polygenic traits with significant heritability driven by central nervous system pathways, rather than just metabolic or muscular factors.

Your natural tendency to be active or sedentary has a genetic component, particularly linked to brain function. This doesn't mean you are stuck; it means you might need to work harder or use different strategies to build activity habits than others. Focus on consistency rather than intensity if starting out.

Pioglitazone, GLP-1 receptor agonists (GLP-1RAs), and SGLT-2 inhibitors are pharmacological agents with potential utility in managing NASH, though GLP-1RAs show more consistent evidence for histological improvement.

If lifestyle changes are insufficient, discuss GLP-1 receptor agonists (like liraglutide or semaglutide) with your doctor. These drugs not only help control blood sugar but have shown the ability to resolve NASH in biopsy-proven cases. They are generally well-tolerated when titrated slowly.

Rapid postnatal catch-up growth in children born with low birth weight or intrauterine growth restriction significantly increases the risk of adult obesity, insulin resistance, and metabolic syndrome.

For parents of small babies, aim for steady, healthy growth rather than rapid weight gain. Monitor growth charts and consult pediatricians to ensure catch-up growth is gradual, as rapid acceleration in infancy is linked to higher risks of obesity and insulin resistance later in life.

Maternal obesity and high pre-pregnancy BMI increase the risk of offspring being overweight, having higher body fat, and exhibiting insulin resistance in childhood, independent of birth weight.

Maintaining a healthy weight before pregnancy is one of the most effective ways to protect your child's long-term metabolic health. If you are overweight, focus on gradual, sustainable lifestyle changes before conception to reduce the risk of your child developing obesity and insulin resistance.

DNA methylation levels in specific genes (e.g., PGC-1α, FTO, TCF7L2) are altered in patients with Type 2 Diabetes and obesity, serving as potential biomarkers for diagnosis and treatment response.

Blood tests measuring DNA methylation patterns (epigenetic biomarkers) may soon help predict who is at risk for diabetes or who will respond to specific drugs like metformin, allowing for more personalized prevention and treatment strategies.

IL-6 acts as a myokine with dual roles: it enhances glucose metabolism and insulin sensitivity during exercise, but chronic overproduction (e.g., in Duchenne muscular dystrophy) contributes to muscle degeneration and inflammation.

IL-6 is a complex myokine. During exercise, it helps your muscles use glucose and fat efficiently. However, in diseases like Duchenne muscular dystrophy, too much IL-6 causes damage. Inhibiting IL-6 in these specific disease contexts can improve muscle health, highlighting that IL-6's effect depends entirely on the physiological context.

Hepatic insulin resistance promotes de novo lipogenesis (DNL) via upregulation of SREBP1c and ChREBP, contributing to liver fat accumulation.

Limiting carbohydrate intake, especially simple sugars, can reduce the substrate and signaling for DNL, thereby lowering liver fat production.

Women exhibit lower biological aging and greater longevity than men, evidenced by molecular biomarkers, higher mitochondrial function, and longer telomeres, despite experiencing higher frailty and worse health outcomes at the end of life.

Biological aging is not identical between sexes. Women generally show molecular signs of slower aging (better mitochondrial function, longer telomeres) and live longer, but often suffer more from frailty and chronic disease in old age. Men may maintain physical function longer but face higher risks of early mortality and specific diseases. Personalized health strategies should account for these inherent biological differences rather than applying a one-size-fits-all approach to aging.

Estrogen and other sex hormones play a protective role in mitochondrial function and aging, with women showing higher mitochondrial gene expression and activity compared to men.

Hormones, particularly estrogen, significantly impact how your cells produce energy and age. Women naturally have more active mitochondria, which contributes to their longer lifespan. As estrogen levels drop after menopause, this protective effect diminishes, potentially accelerating certain aspects of aging. Maintaining metabolic health becomes crucial during this transition.

Telomere length is sexually dimorphic, with women having longer telomeres than men from birth, which may contribute to their longer lifespan, although the causal relationship is complex and influenced by genetics and stress.

Women naturally have longer telomeres, a marker of cellular aging, which may help explain their longer lifespan. However, telomeres shorten due to stress, genetics, and lifestyle factors. While you cannot change your sex, managing stress and maintaining a healthy lifestyle can help preserve telomere length.

Elevated plasma free fatty acids (FFAs) induce endothelial dysfunction primarily by downregulating the AMPK/PI3K/Akt/eNOS signaling pathway, thereby reducing nitric oxide (NO) production and causing vasoconstriction.

If you have metabolic issues like obesity or type 2 diabetes, your body may have high levels of free fatty acids in your blood. This specifically damages the lining of your blood vessels by blocking the production of nitric oxide, which keeps arteries flexible. Managing metabolic health through diet and exercise can lower these fatty acids and protect your vascular function.

Elevated free fatty acids promote endothelial dysfunction by activating inflammatory pathways (NF-κB) and oxidative stress (NADPH oxidase), leading to reduced nitric oxide availability and increased vasoconstrictors like endothelin-1.

High levels of fatty acids in the blood trigger inflammation and oxidative stress in blood vessel walls. This damage reduces the body's ability to produce nitric oxide (a vessel relaxer) and increases substances that tighten vessels. Reducing metabolic stress helps lower this inflammatory burden.

In patients with nonalcoholic steatohepatitis (NASH), circulating bile acid profiles are significantly altered, characterized by increased primary bile acids (specifically conjugated cholate and taurocholate) and decreased secondary bile acids, which correlates with increased severity of hepatic steatosis, inflammation, and fibrosis.

This research highlights that NASH involves specific disruptions in bile acid metabolism, particularly an increase in primary bile acids like cholate and a decrease in secondary ones. While this paper does not prescribe a specific diet, it suggests that the composition of bile acids is a key driver of liver damage. Future interventions may focus on modulating bile acid profiles (e.g., via FXR agonists or dietary fiber to influence microbiome-derived secondary bile acids) to reduce inflammation and fibrosis risk.

PPARgamma activation in immune cells (macrophages, dendritic cells, T cells) suppresses pro-inflammatory signaling pathways (NF-kB, AP-1) via transrepression, reducing the production of inflammatory cytokines like TNF-alpha, IL-1beta, and IL-6.

Chronic inflammation is linked to metabolic disease. PPARgamma activation (naturally or via drugs) helps calm this inflammation by blocking key inflammatory signals in immune cells.

Acarbose treatment improves metabolic parameters (BMI, insulin resistance, lipid profile) in type 2 diabetes patients by altering gut microbiota to increase the ratio of primary to secondary bile acids, but this benefit is contingent on the patient's baseline microbiota composition.

If you are starting treatment for Type 2 Diabetes, ask your doctor about the potential role of your gut health. This research suggests that a specific type of diabetes medication (Acarbose) works better for people who have a certain gut bacteria profile (high Bacteroides). It alters bile acids to improve metabolism, not just blood sugar. This is not a general recommendation for all patients, but a stratification strategy.

Hypertrophic white adipocytes in obesity secrete pro-inflammatory cytokines (TNFα, IL-6, IL-1β) and adipokines (leptin, resistin) that induce local and systemic insulin resistance and chronic inflammation, leading to metabolic disorders like type 2 diabetes and cardiovascular disease.

If you are obese, your fat tissue is actively sending signals that promote inflammation and insulin resistance, which worsens your metabolic health. This is not just 'extra weight'; it is a biologically active state. Addressing obesity through sustainable lifestyle changes can reduce the secretion of these harmful adipokines and improve metabolic markers.

Gut microbiota dysbiosis is associated with the development and severity of specific diabetic complications, including nephropathy, retinopathy, neuropathy, and cardiovascular disease.

Your gut health is linked to your diabetes complications. While high blood sugar is a major factor, your gut bacteria also play a role in inflammation and disease progression. This doesn't mean you are to blame, but it does mean that supporting your gut health (through diet and potentially probiotics) might be part of a comprehensive strategy to protect your kidneys, eyes, and heart.

Testosterone replacement therapy (TRT) is contraindicated in men with untreated prostate or breast cancer, and is not recommended for improving cognitive function, depressive symptoms, or exercise capacity in hypogonadal men.

Do not take testosterone to fix your memory, mood, or physical frailty. It is not effective for these issues. Also, do not take it if you have untreated prostate or breast cancer.